ClinicalTrials.gg
CompletedNCT00752505Updated Dec 4, 2018

A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.

A Phase 2 interventional study of Esreboxetine and Esreboxetine in Fibromyalgia, sponsored by Pfizer. Completed at 7 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-04.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Fibromyalgia by Pfizer — none open to participants now, none under way, none of them phase 3. Fibromyalgia · Pfizer.

Enrollment
9th of 12
89 · median 283
Started
2008
with 3 others
Phase 2
2 of 12
none open now
Registered
8th of 12
by date

Among the 12 studies in Fibromyalgia by Pfizer, this one is the 9th largest by enrollment, is one of 4 that started in 2008, is one of 2 in phase 2, and was the 8th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

None of the 12 studies in Fibromyalgia by Pfizer is open now. The open studies under Fibromyalgia, anywhere →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Fibromyalgia by Pfizer as a file.
02

Study summary

The study is designed to assess if esreboxetine can improve the cognitive function of patients with fibromyalgia. Cognitive function is defined as the ability to concentrate, remember things and make decisions or problem solve. The study is also designed to assess if there is a difference in cognitive function between fibromyalgia patients and matched control subjects.

03

Conditions studied

  • Fibromyalgia

Browse trials for

Keywords

  • Fibromyalgia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have a recognised diagnosis of fibromyalgia, with defined minimum pain criteria. Control subjects must not have a fibromyalgia diagnosis or symptoms and must match fibromyalgia subjects for age, length of education and gender

Exclusion criteria

Exclusion Criteria:

  • Other confounding pain, cognitive disease or impairment, disease that could put the subject at risk or subjects who are on prohibited medications that cannot be washed out.
  • Any subjects with a diagnosis of certain psychiatric disorders in particular major depression or suicidal risk. Matched control subjects have similar exclusions.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    A

    Drug: Esreboxetine

  • Experimental
    B

    Drug: Esreboxetine

Interventions

  • Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing

  • Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing

06

What researchers measure

Primary outcomes

  1. Computer based psychometric tests

    Time frame: 11 week

Secondary outcomes

  1. A questionnaire to evaluate the subjects cognitive status

    Time frame: Once at randomisatoin

  2. A questionnaire to assess the subjects mood

    Time frame: 11 weeks

  3. A question to assess the subjects pain at visits

    Time frame: 11 weeks

  4. A daily diary to assess the subjects pain

    Time frame: 11 weeks

  5. A questionnaire to evaluate the impact the subject perceives fibromyalgia has on their cognitive ability

    Time frame: Once at randomisation

  6. Two questionnaires to assess change in the subjects cognitive ability

    Time frame: 11 weeks

  7. Safety evaluations: medical history, physical and neurological exam, heart rate and blood pressure lying and standing, laboratory tests, electrical heart trace (ECG), adverse event collection, assessment of suicidal risk

    Time frame: 12 weeks

07

Study locations

7 sites
  • Pfizer Investigational Site
    Destin, Florida 32541, United States
  • Pfizer Investigational Site
    Fort Walton Beach, Florida 32547, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48109, United States
  • Pfizer Investigational Site
    Bingham Farms, Michigan 48025, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • Pfizer Investigational Site
    Austin, Texas 78756, United States
  • Pfizer Investigational Site
    Dallas, Texas 75231, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2008
First posted
Sep 15, 2008
Start
Aug 2008
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results delay requested
Jun 7, 2011
Last update
Dec 4, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00752505
Lead sponsor
Pfizer
First posted
Sep 15, 2008
Start date
Aug 2008
Primary completion
Jun 2009
Completion
Jun 2009
Last update
Dec 4, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esreboxetine

Start the discussion